Target (CBDY) Total Current Liabilities (2013 - 2026)
Target (CBDY) reported Total Current Liabilities of $13.8 million for Q1 2026, up 12.0% year-over-year from $12.3 million in Q1 2025, and up 3.31% quarter-over-quarter from $13.4 million in Q4 2025.
Target (CBDY) Total Current Liabilities (2013 - 2026) Analysis & Trends
Target (CBDY) has 14 years of Total Current Liabilities data on file, last reported at $13.8 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $13.8 million, up 12.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.8 million (up 12.0% YoY), and the FY2025 annual result was $13.4 million, up 2.18% from the prior year.
- Total Current Liabilities advanced to $13.8 million in Q1 2026 per CBDY's latest filing, from $13.4 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $14.6 million in Q4 2023 and troughed at $4.4 million in Q2 2022.
- A 5-year average of $10.4 million and a median of $12.3 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities surged 110.6% in 2023, then declined 24.6% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $6.9 million in 2022, then jumped by 110.6% to $14.6 million in 2023, then fell by 10.23% to $13.1 million in 2024, then climbed by 2.18% to $13.4 million in 2025, then grew by 3.31% to $13.8 million in 2026.
- Business Quant data shows CBDY's Total Current Liabilities at $13.8 million in Q1 2026, $13.4 million in Q4 2025, and $12.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.53 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 2.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 831.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 1.66 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 599.50 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 618.78 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 333.17 Mn |
| 10 | Target | - | - | 191,787.00 | 13.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.82 Mn |
| Dec 31, 2025 | 13.38 Mn |
| Sep 30, 2025 | 12.74 Mn |
| Jun 30, 2025 | 9.97 Mn |
| Mar 31, 2025 | 12.34 Mn |
| Dec 31, 2024 | 13.10 Mn |
| Sep 30, 2024 | 13.49 Mn |
| Jun 30, 2024 | 13.22 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Dec 31, 2023 | 14.59 Mn |
| Sep 30, 2023 | 8.41 Mn |
| Jun 30, 2023 | 8.02 Mn |
| Mar 31, 2023 | 7.71 Mn |
| Dec 31, 2022 | 6.93 Mn |
| Sep 30, 2022 | 6.38 Mn |
| Jun 30, 2022 | 4.42 Mn |
| Mar 31, 2022 | 5.13 Mn |
| Dec 31, 2021 | 4.04 Mn |
| Sep 30, 2021 | 3.61 Mn |
| Jun 30, 2021 | 4.35 Mn |